Akademisyen
TUBA HACIBEKİROĞLU
PROFESÖR
SAKARYA ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Hematoloji (İç Hastalıkları)
Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.
- Makale 33
- Proje 0
- Kitap 0
- Bildiri 0
- Patent 0
- Sanatsal 0
Scopus (SJR)
Q1
4
Q2
9
Q3
11
Q4
2
WoS (JCR)
Q1
2
Q2
2
Q3
9
Q4
13
TR Index
5
makale
Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.
Üst %1 makale
1
Üst %10 makale
5
Ort. yüzdelik
57.3%
Üst %1 payı
3.0%
Üst %10 payı
15.2%
Makaleler
YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.
Makale listesi
- 2026 Assessment of characteristics and treatment patterns of adult patients with acquired aplastic anemia in Turkiye (PLANE-TR) YÖKSİS SJR Q2 JCR Q3 OpenAlex 16.3%
- 2026 Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia YÖKSİS SJR Q3 JCR Q4 OpenAlex 46.9%
- 2025 Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety YÖKSİS SJR Q3 JCR Q4 OpenAlex 71.0%
- 2024 Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data YÖKSİS TR Index OpenAlex 14.7%
- 2023 Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 3.0%
- 2023 Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.5%
- 2023 International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report YÖKSİS SJR Q3 JCR Q4 OpenAlex 43.1%
- 2022 The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study. YÖKSİS SJR Q3 JCR Q4 OpenAlex 63.6%
- 2022 The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL. YÖKSİS OpenAlex 67.2%
- 2022 How Did We Organize a Patient Blood Management Outpatient Anemia Unit at Our Hospital? YÖKSİS TR Index SJR Q4 OpenAlex 10.4%
- 2022 The Views of Patients with Hematological Malignancies About Complementary and Alternative Medicine YÖKSİS OpenAlex 62.8%
- 2021 Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients YÖKSİS SJR Q3 JCR Q4 OpenAlex 63.4%
- 2021 The Outcome of COVID‐19 in Patients with Hematological Malignancy YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%
- 2021 Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers YÖKSİS SJR Q1 JCR Q2 OpenAlex 83.4%
- 2021 Covid-19 Enfeksiyonunda Anti-Trombin-3, Protein C ve Protein S Düzeylerinin İncelenmesi YÖKSİS TR Index OpenAlex 6.4%
- 2021 DEMONSTRATION OF SARS-COV-2 IN BONE MARROW CELLS AND CHANGES IN THE HEMATOPOIETIC CELL LINES YÖKSİS SJR Q4 JCR Q4 OpenAlex 39.1%
- 2021 Convalescent plasma therapy in patients with COVID-19 YÖKSİS SJR Q3 JCR Q4 OpenAlex üst %10 OpenAlex 90.7%
- 2021 Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behcet's disease:: evidence of a prethrombotic state YÖKSİS SJR Q2 JCR Q3 OpenAlex 70.0%
- 2021 Covid-19 clinical course and blood groups: Turkish population-based study YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 81.6%
- 2021 Recovery of Symmetrical Peripheral Gangrene of Limbs in a Patient After Performing Hemoadsorption in Septic Shock YÖKSİS SJR Q2 JCR Q4 OpenAlex 74.6%